5 completed, 4 recruiting, 3 active not recruiting, 2 terminated. 7 Phase 3, 2 Phase 1, 2 Phase 2, 2 Phase 4, 1 Not applicable.
Follow Relapsing-remitting Multiple Sclerosis (RRMS): new trials by email Literature Review of Relapsing-remitting Multiple Sclerosis (RRMS) trials Research Report on Relapsing-remitting Multiple Sclerosis (RRMS)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis BCD-281, Ocrelizumab - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Recruiting | Biocad | 292 | 2025-11-01 | 2026-01-06 |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) Ocrelizumab (US), Ocrelizumab (EU), ABP 692 - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Active not recruiting | Amgen | 152 | 2025-01-13 | 2026-09-22 |
| Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis) treatment withdrawal, Usual DMT continuation, MRI - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Not yet recruiting | University Hospital, Strasbourg, France | 200 | 2025-01-01 | 2025-01-03 |
| Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis CLS12311 low, CLS12311 medium, CLS12311 high - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 1 | Completed | Cellerys AG | 11 | 2024-06-18 | 2026-06-08 |
| A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants Relapsing-remitting Multiple Sclerosis (RRMS) | Active not recruiting | Bristol-Myers Squibb | 200 | 2023-06-14 | 2026-05-29 | |
| Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab BeCare application - Relapsing-remitting Multiple Sclerosis (RRMS) | Not applicable | Withdrawn | Icahn School of Medicine at Mount Sinai | 2022-10-31 | 2022-11-25 | |
| Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study Peripheral blood withdrawal - Relapsing-Remitting Multiple Sclerosis (RRMS), Neuromyelitis Optica | Unknown | Neuromed IRCCS | 154 | 2022-04-01 | 2022-02-17 | |
| A Study for Tysabri Participant Preference Natalizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Completed | Biogen | 318 | 2021-10-12 | 2024-05-17 | |
| Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® Intravenous (IV) infusions - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Completed | Polpharma Biologics S.A. | 265 | 2019-10-01 | 2023-07-03 |
| MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) IMU-838 (30 mg/day), IMU-838 (45 mg/day), Placebo - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 2 | Active not recruiting | Immunic AG | 210 | 2019-01-28 | 2024-04-24 |
| Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis MRI, Neurocognitive examination for healthy subjects, blood sampling - Multiple Sclerosis (MS), Relapsing-remitting Multiple Sclerosis (RRMS) | Recruiting | University Hospital, Basel, Switzerland | 300 | 2018-09-04 | 2024-12-16 | |
| Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Daclizumab - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Biogen | 41 | 2017-04-18 | 2019-09-27 |
| Plegridy Satisfaction Study in Participants peginterferon beta-1a - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Completed | Biogen | 193 | 2016-02-03 | 2023-08-31 |
| Brimonidine Tartrate for the Treatment of Injection Related Erythema peginterferon beta-1a, brimonidine tartrate, Vehicle Gel - Relapsing-Remitting Multiple Sclerosis (RRMS) | Phase 4 | Withdrawn | Biogen | 2016-02-01 | 2016-04-25 | |
| Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Arm 1 - GEH120714 (18F) Injection - Relapsing-remitting Multiple Sclerosis (rrMS) | Phase 1 | Completed | GE Healthcare | 30 | 2013-04-01 | 2017-02-24 |
| MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone fingolimod, glatiramer acetate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 3 | Terminated | Novartis Pharmaceuticals | 1064 | 2012-08-09 | 2019-05-28 |
Multiple Sclerosis, Relapsing-Remitting (18) · Multiple Sclerosis (7) · Epstein-Barr Virus Infections (1) · Erythema (1) · Injection Site Reaction (1) · Multiple Sclerosis, Chronic Progressive (1) · Neuromyelitis Optica (1) · Recurrence (1)
Autoimmune Diseases (18) · Autoimmune Diseases of the Nervous System (18) · Demyelinating Autoimmune Diseases, CNS (18) · Demyelinating Diseases (18) · Immune System Diseases (18) · Nervous System Diseases (18) · Multiple Sclerosis (11) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Disease Attributes (2) · Chemically-Induced Disorders (1) · Chronic Disease (1) · Cranial Nerve Diseases (1) · DNA Virus Infections (1) · Drug-Related Side Effects and Adverse Reactions (1)
ocrelizumab (3) · Dimethyl Fumarate (2) · Glatiramer Acetate (2) · peginterferon beta-1a (2) · Blood Specimen Collection (1) · Brimonidine Tartrate (1) · Coat Protein Complex I (1) · Daclizumab (1) · Fingolimod Hydrochloride (1) · Injections (1) · Interferon-beta (1) · Natalizumab (1) · Rituximab (1) · Tablets (1) · ofatumumab (1)
Biogen (4) · Amgen (1) · Biocad (1) · Bristol-Myers Squibb (1) · Cellerys AG (1) · GE Healthcare (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Icahn School of Medicine at Mount Sinai (1) · Immunic AG (1) · Neuromed IRCCS (1) · Novartis Pharmaceuticals (1) · Polpharma Biologics S.A. (1) · University Hospital, Basel, Switzerland (1) · University Hospital, Montpellier (1) · University Hospital, Strasbourg, France (1)
Italy (5) · Canada (4) · Germany (4) · United States (4) · France (3) · Poland (3) · Switzerland (3) · Ukraine (3) · Bulgaria (2) · Croatia (2) · Czechia (2) · Georgia (2) · Puerto Rico (2) · Romania (2) · Serbia (2)
Andreas Muehler (1) · Cristina Granziera, Prof. Dr. med. (1) · De-Cai Tian, M.D., Ph.D. (1) · Fabio Buttari, PhD (1) · Karsten Roth, Dr. (1) · Laura Tabacof, MD (1) · Paul Sherwin, M.D. (1)
PMID 32852530, PMID 35698927, PMID 36689214, PMID 38616781, PMID 38662979, PMID 39749348
2015 (2), 2018 (2), 2016 (1)